Dilantin Infatab is a medicine containing the active ingredient(s) phenytoin. On this page you will find out more about Dilantin Infatab, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
Dilantin (phenytoin sodium) 30 & 100 mg capsule bottles and Dilantin (phenytoin) Infatabs 50 mg tablet bottle
Recall Action Commencement Date: 2/12/2016
Multiple lots affected
TGA Recall Reference: RC-2016-RN-01523-1
Dilantin (phenytoin sodium) 30 mg capsule bottle
AUST R Number: 14306
Dilantin (phenytoin sodium) 100 mg capsule bottle
AUST R Number: 14305
Dilantin (phenytoin) Infatabs 50 mg tablet bottle
AUST R Number: 14308
Further information on this recall can be found at http://apps.tga.gov.au/PROD/SARA/arn-detail.aspx?k=RC-2016-RN-01523-1
Active ingredient in this medicine: phenytoin
Information for medicine and pack size:
Dilantin Infatab 50 mg chewable tablet, 200
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
DILANTIN is indicated for the control of grand mal and psychomotor seizures. DILANTIN will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. Besides its effectiveness in controlling seizures, DILANTIN frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that DILANTIN is valuable in the prevention of seizures occurring during or after neurosurgery and in the treatment of certain cardiac arrythmias. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see Dosage and Administration).
Table of characteristics
a yellow triangular tablet with flat sides bevelled edges, break bar on one side and 'P-D' on the other
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, chewable|
|Route of administration||Oral|
200: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||No information available|
|Life time||3 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 February 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.